STAT Expert Advantage
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
Related Articles
Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs
Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1…
Health care costs: one of the biggest obstacles to reshoring American industry
If the U.S. is serious about reshoring manufacturing jobs, it needs to address the factors that lead to offshoring those jobs in the first place,…
FDA chief’s goals of ‘radical transparency’ threatened by agency cuts
FDA chief wants more transparency and fewer conflicts of interest. Staff warn cuts may do the opposite.
The decades-long journey to Gilead’s twice-a-year HIV prevention drug lenacapavir
Gilead’s twice-a-year HIV prevention drug lenacapavir is 30 years in the making. Here’s the story behind it.
Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official
The ouster of the FDA’s chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a drug review, STAT…
Why MAHA wants whole milk back on the table
In the nutrition world, the question of how whole milk compares with lower-fat options is the subject of debate. In MAHA world, it’s time to…
Novo Nordisk’s amylin obesity drug keeps performing like Zepbound
Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.
Nabla raises $70 million as market for AI tools to help doctors heats up
AI developer Nabla has raised $70 million as the company looks to expand the capabilities of its software that automates clinical documentation.
Zealand’s GLP-2 candidate shows early weight loss results
Zealand Pharma said that its obesity candidate that uses a unique mechanism led to notable weight loss in an early trial.
Bill Gates: I lost my father to Alzheimer’s. But I’m more optimistic than ever about fighting the disease
Bill Gates writes: “We are on the cusp of turning the tide against dementia — which makes this an especially bad time to pull back…